TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Antibiotic days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Qualitative response to the system
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decreased bone density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum level of Lp-PLA2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fasting plasma glucose level (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hemoglobin A1c level (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Chronic pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Swollen Joint Count at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percent Change From Baseline in Tender Joint Count at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Apnea Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Neurocognitive Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absolute Plasma Glucose Area Under the Curve (AUC) 0-3hr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing a Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum observed blood concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to reach maximum blood concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the blood concentration versus time curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Posttreatment Yale-Brown Obsessive Compulsive Scale (Y-BOCS) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in laser flare and cell measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pulmonary function testing values (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants Who Achieved Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of clopidogrel resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-risk subgroups of adverse clinical outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Aedes-borne virus (ABV) infection
Endpoint domain: Adverse events/effects
Primary endpoint: Loss of independence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in score on the Decisional Conflict Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Unconfirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Confirmed Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Graft take after tympanoplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of genetic variants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of anxiety symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: CD34+ hematopoietic progenitor cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Thiobarbituric Acid Reactive Substance (TBARS) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Adiponectin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Urinary Concentrations of Transforming Growth Factor-beta1 (TGF-beta1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recovery of the train-of-four ratio (TOF) to 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State rumination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Venous Thromboembolisms and/or Major Hemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in PA Spine Bone Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AUC0-t (Area Under the Plasma Concentration-time Curve From Time 0 to t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bit rate in bits per minute
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain During the Pelvic Floor Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Who Achieve a Peak Esophageal Intraepithelial Count of ≤6 Eosinophils/Hpf at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Dysphagia Symptom Questionnaire (DSQ) Score From Baseline to Weeks 23-24
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: post operative residual astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 72 hour fluid removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alveolar Nitric Oxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Subjects With a Weight Loss of at Least 5% at Week 56 With LOCF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in left ventricular stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: success without posterior wall puncture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: success in first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: PrEP knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Circulating levels of Inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of changes of AUC, trough Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Voice-Related Quality Of Life (VRQOL) Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mean amplitude of glycemic excursions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intracranial Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: taste detection thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: capsaicin cough sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary Protein values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Urinary Sediment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relative post-exercise and post-rest energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: subjective bother of lichenoid disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PODS free days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: alive
Endpoint domain: Mortality/survival
Primary endpoint: Performance on Standardized Neuropsychological Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HBV specific T-cell response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with adverse events at short term
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with adverse events at mid/long term
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of the PVC placement procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fracture classification (AO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fracture classification (NEER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dash score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: QoL 36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of HIV patients with bone fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in upper gastrointestinal symptoms (SF-LDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in upper gastrointestinal symptoms (GCSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Detection of placenta accreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: change in number of cluster headache attacks per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal exercise tolerance (walking distance in the 6-minute walking test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripheral oxygen saturation (SatO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulmonary-systemic ratio of arterial resistance (Rp:Rs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial glycaemic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal death due to PPH
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in pain using Visual Analogue Scores (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Successfully Placed EASI Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Systemic Absorption of Subcutaneously Administered Tracer-labelled Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in serum natural killer cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gut microbial composition and diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Absolute Change in Percent-predicted Forced Expiratory Volume in One Second (ppFEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PTAs of AUC24/MIC90 for C. albicans, C. glabrata, and C. parapsilosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PTAs of AUC24/MIC for various species of Candida spp isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: PTAs of trough concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cardiovascular readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Heart failure readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Safety / maximum tolerated dose
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in the number of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: The maximum observed plasma concentration of GLPG1972 (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The time (tmax) to reach Cmax of GLPG1972
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of Abemaciclib and Active Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Abemaciclib and Active Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dysexecutive functioning - participants' report
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cognitive failures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in dysexecutive functioning - carers' report
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: MenC-specific IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ELISPOT Response to Gag and Nef
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Urinary Oxalate Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Adequate intubation condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tissue integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of oral cotrimoxazole in idiopathic pulmonary fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of the number of angina attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of chemotherapy dose delay or reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of grade 3 and above toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: MCP-1:Creatinine Ratio in Urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Restoration of blood cell count (in absence of growth factors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: work incapacity
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Bowel cleanness based on % of mucosal surface visualized
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Simple Endoscopic Score for Crohn's Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Levels of Faecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Objective Response (Non-Osteosarcoma Strata)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Response (Osteosarcoma Stratum)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 1 year chronic GVHD-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Temporomandibular joint pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at Time of Uterine Evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quo 40 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: resolution of basal cell carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total number of educational points addressed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peak FEV1 Within 3 Hours Post-dose Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: The Responder Rate as Assessed by the ACQ
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients With Oxaliplatin-induced Grade 2+ Chronic Neuropathic Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Fugl Meyer Assessment - Upper Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Normal Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Patients With Hypoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of Patients With Hypoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensitivity of Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events of Grade 3 and Grade 4
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment discontinuations, modifications, and interruptions due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Dichotomized Glasgow Outcome Scale Extended (GOS-E) at 6 Months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean change from baseline in patient weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intracranial progression free survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: absolute change in platelet activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average compression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of prolongation of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Patient's rating of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's evaluation of pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's global satisfaction assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With MRD Negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total post operative narcotic use in morphine equivalents
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Differences in the electrocardiographic QRS axis shift(°)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differences in the electrocardiographic rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Differences in the CO-RADS5/CO-RADS1-4 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cure of the target toe nail
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage Change of the BOLD Signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QIDS-16: Quick Inventory of Depressive Symptomatology Self-Rated (QIDS-16)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in subjective pain level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with seroresponse to meningococcal serogroups A,C and Haemophilus b post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of adverse events during a 30 day follow-up period after each vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Child Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in child fruit, vegetable, and sugary beverage intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in child physical activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute toxicity of SABR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Adverse events/effects
Primary endpoint: Acute quality of life during and after SABR
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in biomarkers of appetite regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reactive Hyperemia Index (RHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anthropometric Measures of Nutritional Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radial Artery Cross Sectional Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes